Global Gastrointestinal Diseases Therapeutics Market 2022-2026

The gastrointestinal diseases therapeutics market is poised to grow by $1.60 bn during 2022-2026, accelerating at a CAGR of 6.68% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and increasing demand for biologics and targeted therapies.

The gastrointestinal diseases therapeutics market analysis includes the product segment and geographic landscape.

The gastrointestinal diseases therapeutics market is segmented as below:

By Product

Anti-inflammatory and immunosuppressors
Acid neutralizers
Other therapeutics

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, funding for gastrointestinal research studies and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.

The report on the gastrointestinal diseases therapeutics market covers the following areas:

Gastrointestinal diseases therapeutics market sizing
Gastrointestinal diseases therapeutics market forecast
Gastrointestinal diseases therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Biogen Inc., Boston Scientific Corp., C. H. Boehringer Sohn AG and Co. KG, Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., OVESCO ENDOSCOPY AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Drug Class

5.1 Market segments
Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)
5.2 Comparison by Drug Class
Exhibit 26: Chart on Comparison by Drug Class
Exhibit 27: Data Table on Comparison by Drug Class
5.3 Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026
Exhibit 28: Chart on Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Anti-inflammatory and immunosuppressors - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Anti-inflammatory and immunosuppressors - Year-over-year growth 2021-2026 (%)
5.4 Acid neutralizers - Market size and forecast 2021-2026
Exhibit 32: Chart on Acid neutralizers - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Acid neutralizers - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Acid neutralizers - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Acid neutralizers - Year-over-year growth 2021-2026 (%)
5.5 Other therapeutics - Market size and forecast 2021-2026
Exhibit 36: Chart on Other therapeutics - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Other therapeutics - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Other therapeutics - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Other therapeutics - Year-over-year growth 2021-2026 (%)
5.6 Market opportunity by Drug Class
Exhibit 40: Market opportunity by Drug Class ($ million)

6 Customer Landscape

6.1 Customer landscape overview
Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
Exhibit 42: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 44: Chart on Geographic comparison
Exhibit 45: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Japan - Market size and forecast 2021-2026
Exhibit 66: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on Japan - Year-over-year growth 2021-2026 (%)
7.9 China - Market size and forecast 2021-2026
Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
7.10 Germany - Market size and forecast 2021-2026
Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.11 France - Market size and forecast 2021-2026
Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 82: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 83: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape

9.1 Overview
9.2 Vendor landscape
Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 85: Overview on factors of disruption
9.4 Industry risks
Exhibit 86: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
Exhibit 87: Vendors covered
10.2 Market positioning of vendors
Exhibit 88: Matrix on vendor position and classification
10.3 Abbott Laboratories
Exhibit 89: Abbott Laboratories - Overview
Exhibit 90: Abbott Laboratories - Business segments
Exhibit 91: Abbott Laboratories - Key news
Exhibit 92: Abbott Laboratories - Key offerings
Exhibit 93: Abbott Laboratories - Segment focus
10.4 AbbVie Inc.
Exhibit 94: AbbVie Inc. - Overview
Exhibit 95: AbbVie Inc. - Product/Service
Exhibit 96: AbbVie Inc. - Key offerings
10.5 AstraZeneca Plc
Exhibit 97: AstraZeneca Plc - Overview
Exhibit 98: AstraZeneca Plc - Product/Service
Exhibit 99: AstraZeneca Plc - Key news
Exhibit 100: AstraZeneca Plc - Key offerings
10.6 Bausch Health Co Inc
Exhibit 101: Bausch Health Co Inc - Overview
Exhibit 102: Bausch Health Co Inc - Business segments
Exhibit 103: Bausch Health Co Inc - Key news
Exhibit 104: Bausch Health Co Inc - Key offerings
Exhibit 105: Bausch Health Co Inc - Segment focus
10.7 C. H. Boehringer Sohn AG and Co. KG
Exhibit 106: C. H. Boehringer Sohn AG and Co. KG - Overview
Exhibit 107: C. H. Boehringer Sohn AG and Co. KG - Business segments
Exhibit 108: C. H. Boehringer Sohn AG and Co. KG - Key news
Exhibit 109: C. H. Boehringer Sohn AG and Co. KG - Key offerings
Exhibit 110: C. H. Boehringer Sohn AG and Co. KG - Segment focus
10.8 GlaxoSmithKline Plc
Exhibit 111: GlaxoSmithKline Plc - Overview
Exhibit 112: GlaxoSmithKline Plc - Business segments
Exhibit 113: GlaxoSmithKline Plc - Key news
Exhibit 114: GlaxoSmithKline Plc - Key offerings
Exhibit 115: GlaxoSmithKline Plc - Segment focus
10.9 Johnson and Johnson
Exhibit 116: Johnson and Johnson - Overview
Exhibit 117: Johnson and Johnson - Business segments
Exhibit 118: Johnson and Johnson - Key news
Exhibit 119: Johnson and Johnson - Key offerings
Exhibit 120: Johnson and Johnson - Segment focus
10.10 Merck and Co. Inc.
Exhibit 121: Merck and Co. Inc. - Overview
Exhibit 122: Merck and Co. Inc. - Business segments
Exhibit 123: Merck and Co. Inc. - Key news
Exhibit 124: Merck and Co. Inc. - Key offerings
Exhibit 125: Merck and Co. Inc. - Segment focus
10.11 Takeda Pharmaceutical Co. Ltd.
Exhibit 126: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 127: Takeda Pharmaceutical Co. Ltd. - Product/Service
Exhibit 128: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 129: Takeda Pharmaceutical Co. Ltd. - Key offerings
10.12 UCB SA
Exhibit 130: UCB SA - Overview
Exhibit 131: UCB SA - Product/Service
Exhibit 132: UCB SA - Key offerings

11 Appendix

11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 133: Inclusions checklist
Exhibit 134: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 135: Currency conversion rates for US$
11.4 Research methodology
Exhibit 136: Research methodology
Exhibit 137: Validation techniques employed for market sizing
Exhibit 138: Information sources
11.5 List of abbreviations
Exhibit 139: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between 2021 and 2026
Exhibits 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Drug Class - Market share 2021-2026 (%)
Exhibits 25: Data Table on Drug Class - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Drug Class
Exhibits 27: Data Table on Comparison by Drug Class
Exhibits 28: Chart on Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Anti-inflammatory and immunosuppressors - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Anti-inflammatory and immunosuppressors - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Acid neutralizers - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Acid neutralizers - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Acid neutralizers - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Acid neutralizers - Year-over-year growth 2021-2026 (%)
Exhibits 36: Chart on Other therapeutics - Market size and forecast 2021-2026 ($ million)
Exhibits 37: Data Table on Other therapeutics - Market size and forecast 2021-2026 ($ million)
Exhibits 38: Chart on Other therapeutics - Year-over-year growth 2021-2026 (%)
Exhibits 39: Data Table on Other therapeutics - Year-over-year growth 2021-2026 (%)
Exhibits 40: Market opportunity by Drug Class ($ million)
Exhibits 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 42: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 44: Chart on Geographic comparison
Exhibits 45: Data Table on Geographic comparison
Exhibits 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 48: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on Japan - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 78: Chart on France - Market size and forecast 2021-2026 ($ million)
Exhibits 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
Exhibits 80: Chart on France - Year-over-year growth 2021-2026 (%)
Exhibits 81: Data Table on France - Year-over-year growth 2021-2026 (%)
Exhibits 82: Market opportunity By Geographical Landscape ($ million)
Exhibits 83: Impact of drivers and challenges in 2021 and 2026
Exhibits 84: Overview on Criticality of inputs and Factors of differentiation
Exhibits 85: Overview on factors of disruption
Exhibits 86: Impact of key risks on business
Exhibits 87: Vendors covered
Exhibits 88: Matrix on vendor position and classification
Exhibits 89: Abbott Laboratories - Overview
Exhibits 90: Abbott Laboratories - Business segments
Exhibits 91: Abbott Laboratories - Key news
Exhibits 92: Abbott Laboratories - Key offerings
Exhibits 93: Abbott Laboratories - Segment focus
Exhibits 94: AbbVie Inc. - Overview
Exhibits 95: AbbVie Inc. - Product/Service
Exhibits 96: AbbVie Inc. - Key offerings
Exhibits 97: AstraZeneca Plc - Overview
Exhibits 98: AstraZeneca Plc - Product/Service
Exhibits 99: AstraZeneca Plc - Key news
Exhibits 100: AstraZeneca Plc - Key offerings
Exhibits 101: Bausch Health Co Inc - Overview
Exhibits 102: Bausch Health Co Inc - Business segments
Exhibits 103: Bausch Health Co Inc - Key news
Exhibits 104: Bausch Health Co Inc - Key offerings
Exhibits 105: Bausch Health Co Inc - Segment focus
Exhibits 106: C. H. Boehringer Sohn AG and Co. KG - Overview
Exhibits 107: C. H. Boehringer Sohn AG and Co. KG - Business segments
Exhibits 108: C. H. Boehringer Sohn AG and Co. KG - Key news
Exhibits 109: C. H. Boehringer Sohn AG and Co. KG - Key offerings
Exhibits 110: C. H. Boehringer Sohn AG and Co. KG - Segment focus
Exhibits 111: GlaxoSmithKline Plc - Overview
Exhibits 112: GlaxoSmithKline Plc - Business segments
Exhibits 113: GlaxoSmithKline Plc - Key news
Exhibits 114: GlaxoSmithKline Plc - Key offerings
Exhibits 115: GlaxoSmithKline Plc - Segment focus
Exhibits 116: Johnson and Johnson - Overview
Exhibits 117: Johnson and Johnson - Business segments
Exhibits 118: Johnson and Johnson - Key news
Exhibits 119: Johnson and Johnson - Key offerings
Exhibits 120: Johnson and Johnson - Segment focus
Exhibits 121: Merck and Co. Inc. - Overview
Exhibits 122: Merck and Co. Inc. - Business segments
Exhibits 123: Merck and Co. Inc. - Key news
Exhibits 124: Merck and Co. Inc. - Key offerings
Exhibits 125: Merck and Co. Inc. - Segment focus
Exhibits 126: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits 127: Takeda Pharmaceutical Co. Ltd. - Product/Service
Exhibits 128: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits 129: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits 130: UCB SA - Overview
Exhibits 131: UCB SA - Product/Service
Exhibits 132: UCB SA - Key offerings
Exhibits 133: Inclusions checklist
Exhibits 134: Exclusions checklist
Exhibits 135: Currency conversion rates for US$
Exhibits 136: Research methodology
Exhibits 137: Validation techniques employed for market sizing
Exhibits 138: Information sources
Exhibits 139: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global gastrointestinal diseases therapeutics market: Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Biogen Inc., Boston Scientific Corp., C. H. Boehringer Sohn AG and Co. KG, Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., OVESCO ENDOSCOPY AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is strong product pipeline.`

According to the report, one of the major drivers for this market is the increasing incidence of gastrointestinal diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.